{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:48Z","timestamp":1762865808267},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.thromres.2011.06.008","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T23:37:58Z","timestamp":1310168278000},"page":"17-21","source":"Crossref","is-referenced-by-count":8,"title":["Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience"],"prefix":"10.1016","volume":"129","author":[{"given":"Marc","family":"Schindewolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2011.06.008_bb0005","first-page":"30","article-title":"Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs","volume":"350","author":"Petitou","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2011.06.008_bb0010","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2011.06.008_bb0015","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Harrington","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2011.06.008_bb0020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH09-01-0008","article-title":"Prescription of fondaparinux in hospitalised patients","volume":"101","author":"Baroletti","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.4065\/mcp.2010.0346","article-title":"Low allergenic potential with fondaparinux: Results of a prospective investigation","volume":"85","author":"Schindewolf","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.thromres.2011.06.008_bb0030","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(95)92535-X","article-title":"Accuracy of clinical assessment of deep-vein thrombosis","volume":"345","author":"Wells","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2011.06.008_bb0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0037-1614536","article-title":"First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4\/heparin ELISA","volume":"81","author":"Eichler","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arth.2005.05.023","article-title":"Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery","volume":"21","author":"Colwell","year":"2006","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.thromres.2011.06.008_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00068-005-1442-0","article-title":"Prophylaxis, diagnosis and therapy of surgery-related complications in orthopedic and trauma surgery","volume":"31","author":"Bauersachs","year":"2005","journal-title":"Eur J Trauma Emerg Surg"},{"key":"10.1016\/j.thromres.2011.06.008_bb0065","first-page":"70","article-title":"Use of fondaparinux in patients with heparin-induced thrombocytopenia type II","volume":"35","author":"Schindewolf","year":"2006","journal-title":"VASA"},{"key":"10.1016\/j.thromres.2011.06.008_bb0070","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2011.06.008_bb0075","first-page":"168","article-title":"Fondaparinux-related thrombocytopenia in a patient with former HIT","volume":"100","author":"Schindewolf","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0080","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2011.06.008_bb0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0090","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2008.02973.x","article-title":"Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal","volume":"6","author":"Elalamy","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0095","first-page":"A10","article-title":"German Registry for use of fondaparinux in HIT or suspected HIT - preliminary data","volume":"31","author":"Schindewolf","year":"2011","journal-title":"Haemostaseologie"},{"key":"10.1016\/j.thromres.2011.06.008_bb0100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4T's score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0105","first-page":"37","article-title":"Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective","volume":"36","author":"Blakeman","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.thromres.2011.06.008_bb0110","unstructured":"http:\/\/www.onlinelawyersource.com\/heparin\/heparin-induced-thrombocytopenia.html."},{"key":"10.1016\/j.thromres.2011.06.008_bb0115","unstructured":"http:\/\/www.heparinfacts.com\/requestassist.htm."},{"key":"10.1016\/j.thromres.2011.06.008_bb0120","unstructured":"http:\/\/www.adrugrecall.com\/heparin\/induced-thrombocytopenia-lawsuit.html."},{"key":"10.1016\/j.thromres.2011.06.008_bb0125","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1378\/chest.08-0120","article-title":"The financial impact of heparin-induced thrombocytopenia","volume":"134","author":"Smythe","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2011.06.008_bb0130","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2009.03317.x","article-title":"The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis","volume":"7","author":"Wilke","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bjs.4809","article-title":"Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro","volume":"92","author":"Handschin","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.thromres.2011.06.008_bb0140","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2011.06.008_bb0145","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1160\/TH05-05-0318","article-title":"Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides","volume":"94","author":"Ludwig","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1468-3083.2007.02333.x","article-title":"Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin","volume":"22","author":"Schindewolf","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.thromres.2011.06.008_bb0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.0105-1873.2003.0185a.x","article-title":"Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans","volume":"49","author":"Ludwig","year":"2003","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.thromres.2011.06.008_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-1873.2004.00399.x","article-title":"Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases","volume":"51","author":"Jappe","year":"2004","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.thromres.2011.06.008_bb0165","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2174\/138161205774580552","article-title":"Heterogeneity of synthetic factor Xa inhibitors","volume":"11","author":"Gerotziafas","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.thromres.2011.06.008_bb0170","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/j.1538-7836.2007.02729.x","article-title":"Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT)","volume":"5","author":"Dunn","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0175","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.thromres.2011.06.008_bb0180","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials","volume":"101","author":"van Doormaal","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH05-07-0515","article-title":"The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo","volume":"95","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0190","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.06.008_bb0195","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2011.06.008_bb0200","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.thromres.2011.06.008_bb0205","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins\u2013correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811002957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811002957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T06:24:12Z","timestamp":1592720652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384811002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0049384811002957"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2011.06.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}